{"url_path":"/sec/mgnx/8-k/2026-05-20/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-20","source_url":"https://www.sec.gov/Archives/edgar/data/1125345/0001125345-26-000042-index.html","accession_number":"0001125345-26-000042","cik":"0001125345","ticker":"MGNX","issuer_name":"MACROGENICS INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1125345/0001125345-26-000042-index.html","primary_entity_key":"0001125345","primary_entity_name":"MACROGENICS INC"},"word_count":344,"has_tables":true,"body_markdown":"Item 5.07\nSubmission of Matters to a Vote of Security Holders.\n\nMacroGenics, Inc. (the \"Company\") held its 2026 Annual Meeting of Stockholders on May 19, 2026. A total of 36,744,013 shares of the Company's common stock were present or represented by proxy at the meeting, which represented approximately 58% of the Company's 63,560,068 shares of common stock that were outstanding and entitled to vote at the meeting as of the record date of March 27, 2026. Stockholders considered the four proposals outlined below, each of which is described in more detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on April 8, 2026 (the \"Proxy Statement\").\n\nProposal 1. The election of four nominees to serve as Class I directors, each for a term of three years. All director nominees were elected. The voting results were as follows:\n\nNomineesForWithheldBroker Non-Votes\n\nScott Koenig, M.D., Ph.D.26,353,906992,3999,397,708\n\nFederica O'Brien26,467,370878,9359,397,708\n\nEric Risser27,174,501171,8049,397,708\n\nProposal 2. The ratification of the appointment by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for fiscal year 2026. Proposal 2 was approved. The voting results were as follows:\n\nForAgainstAbstainBroker Non-Votes\n\n36,689,68340,55213,778—\n\nProposal 3. To approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Company's Proxy Statement. Stockholders approved the compensation of the Company's named executive officers. The voting results were as follows:\n\nForAgainstAbstainBroker Non-Votes\n\n26,624,952526,125195,2289,397,708\n\nProposal 4. To approve an amendment to the MacroGenics, Inc. 2023 Equity Incentive Plan (the \"2023 Plan\") to increase the number of shares of our common stock available for issuance thereunder by 1,250,000 shares. Stockholders approved the amendment to the 2023 Plan. The voting results were as follows:\n\nForAgainstAbstainBroker Non-Votes\n\n25,600,1121,671,10275,0919,397,708\n\nSIGNATURE\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\nMACROGENICS, INC.\n\nDate: May 20, 2026\nBy:\n\nName:\n\nTitle:\n\n/s/ Jeffrey Peters\n\nJeffrey Peters\n\nSenior Vice President, General Counsel and Corporate Secretary"}